Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Posted inAllergy & Immunology Neurology news

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–moderate AD.
Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases
Posted inAllergy & Immunology Clinical Updates Family Medicine & Nutrition news Specialties

Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases

Low-dose IL-2 immunotherapy demonstrates broad, disease-modifying effects by selectively expanding regulatory T cells (Tregs), offering a promising strategy across diverse diseases including autoimmunity, neurodegeneration, metabolic dysfunction, transplantation, and inflammatory disorders.